An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. LONDON (AP) — The ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

TODAY i have some great news to share. Besides the fact that last week was the King's Birthday, something exciting was happening in the HIV ...

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...

European regulators have greenlit a twice-yearly injection to prevent HIV that has been hailed as a game-changer in the ...

The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.